ArticleAnnals of surgical oncology2026
Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeoadjuvant therapy can improve the survival outcomes of patients with borderline resectable pancreatic cancer (BRPC). However, standard neoadjuvant regimens remain lacking. This study evaluated the clinical feasibility of tislelizumab plus gemcitabine and nab-paclitaxel in the neoadjuvant setting for BRPC. PATIENTS AND
methodsIn this prospective study, patients with BRPC preoperatively received three cycles of tislelizumab plus gemcitabine and nab-paclitaxel, and continued postoperatively. The primary endpoints were R0 resection rate and treatment-related adverse events (TRAEs). Exploratory objectives were resistance to this regimen.
resultsOf 30 enrolled patients, 80.0% (24/30) completed neoadjuvant therapy and underwent surgical resection. R0 resection was achieved in 80.0% (24/30) of the patients and in 100.00% (24/24) of those resected. The 12-month OS and RFS rates were 87.5% (95% CI 64.3-95.8%) and 82.8% (95% CI 60-95.8%), respectively, with median RFS of 28 months (95% CI 16.9-39.1). Most TRAEs were grade I-II, with no serious events. Quantitative proteomics combined with machine learning identified NT5DC2, FAM3D, CXCL5, and TMT1B as candidate biomarkers of resistance to this neoadjuvant regimen. In paired pre- and postoperative tissues from treatment-sensitive patients, CD8
conclusionsNeoadjuvant tislelizumab plus gemcitabine and nab-paclitaxel is promising for improving the resection rate in BRPC, with a favorable safety profile. NT5DC2, FAM3D, CXCL5, and TMT1B may serve as candidate biomarkers of preoperative drug resistance, and tumor immune microenvironment (TIME) analysis further reveals immune microenvironment remodeling in postoperative tumors from treatment-sensitive patients. These findings warrant validation in larger-scale studies. Trial Registration Chinese Clinical Trial registry (ChiCTR2200063680).
Indexed as
Identifiers
42862523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.